Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, comments on the major unmet needs for patients with multiple myeloma, noting that the medical need has shifted from triple-class refractory patients to those who are refractory to T-cell engagers and CAR-Ts. He emphasizes the importance of optimizing the sequencing of agents to achieve the best bridging therapy for these patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
